一、基本信息
闵鉴，博士，讲师
邮箱：jianmin@hubu.edu.cn
研究方向：抗肿瘤（乳腺癌）药物的设计、合成与开发，和结构新颖、具有雌激素受体细胞特异信号调控功能的小分子及药物先导结构的设计和优化研究。
二、教育背景
2008.09–2013.12 武汉大学药学院，理学博士，生物化学与分子生物学，导师：周海兵 教授
2004.09–2008.07 武汉大学药学院，理学学士，药学
三、工作经历
2018.09至今 湖北大学生命科学学院，讲师
2014.11–2018.08 美国伊利诺伊大学香槟分校，博士后研究员，导师：John Katzenellenbogen 教授
2012.02–2013.02 美国伊利诺伊大学香槟分校（UIUC），访问****
三、承担科研项目情况
1. 中国博士后基金，2020M672435，靶向ESR1突变耐药的新型双机制ERα拮抗剂的设计、合成及生物活性研究，2020.07–2021.12，8万元，在研，主持
2. 湖北省自然科学基金青年基金，2019CFB385，基于PROTAC策略的抗耐药性乳腺癌药物的设计、合成及生物活性研究，2019.01–2020.12，3万元，在研，主持
3. Chemical, structural and molecular rules for fully antagonizing the estrogen receptor，R01-CA220284，$420,820/年，美国国家卫生研究所(NIH, USA)，2018年至2023年，主要技术骨干
4. Antiestrogens for Metastatic Breast Cancers Driven by Estrogen Receptors with Activating Mutations，BCRF 17-083，$100,000/年，美国乳腺癌研究基金会 (Breast Cancer Research Foudation)，2016–2019，主要技术骨干
5. Novel ligands and mechanisms to achieve selective nuclear receptor activity，R01-DK015556，$411,011/年,美国国家卫生研究所(NIH, USA)，2014–2019年，主要技术骨干
6. 国家自然科学基金委员会，面上项目，**，雌激素受体的小分子双重调控及相关药物研究，2014.01–2017.12，62万元，结题，参加
7. 国家自然科学基金委员会，面上项目，**，新型双功能磁性纳米探针介导雌激素受体非基因组效应及分子影像学研究，2012.01–2015.12，58万元，结题，参加
四、发表论文和专利
1. Chen CC ^#, Min, J.; ^# Zhang, L.; ^# Yang, Y.; Yu, X.; * Guo, R. T.* Advanced Understanding of the Electron Transfer Pathway of Cytochrome P450s. ChemBioChem, 2021, 22, 1317-1328 (共同第一作者，封面文章)
2. Hu, Y.; ^# Xue, J.; ^# Min, J.; ^# Qin, L.; Zhang, J.; * Dai, L. * Biocatalytic synthesis of ginsenoside Rh2 using Arabidopsis thaliana glucosyltransferase-catalyzed coupled reactions. Journal of Biotechnology, 2020, 309, 107-112. (共同第一作者)
3. Hu, Y.; ^# Min, J.; ^# Qu, Y.; Zhang, X.; Zhang, J.; * Dai, L. * Biocatalytic synthesis of calycosin-7-O-β-D-glucoside with UDP-glucose regeneration system. Catalysts, 2020, 10: 258. (共同第一作者)
4. Min, J.; ^# Guillen, V. S.; Sharma, A.; Zhao, Y.; Ziegler, Y.; Gong, P.; Mayne, C. G.; Srinivasan, S.; Kim, S. H.; Carlson, K. E.; Nettles, K. W.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A.* Adamantyl Antiestrogens with Novel Side Chains Reveal a Spectrum of Activities in Suppressing Estrogen Receptor Mediated Activities in Breast Cancer Cells. Journal of Medicinal Chemistry, 2017, 60 (14), 6321-6336. (第一作者，药物化学一区)
5. Min, J.; ^# Wang, P.; Srinivasan, S.; Nwachukwu, J. C.; Guo, P.; Huang, M.; Carlson, K. E.; Katzenellenbogen, J. A.; * Nettles, K. W.; Zhou, H.-B., * Thiophene-Core Estrogen Receptor Ligands Having Superagonist Activity. Journal of Medicinal Chemistry, 2013, 56 (8), 3346-3366. (第一作者，药物化学一区)
6. Chen, C. C.; ^# Han, X.; ^# Li, X.; ^# Jiang, P.; Niu, D.; Ma, L.; Liu, W.; Li, S.; Qu, Y.; Hu, H.; Min, J.; Yang, Y.; Zhang, L.; Zeng, W.; Huang, J. W.;* Dai, L.;* Guo, R. T.* General features to enhance enzymatic activity of poly (ethylene terephthalate) hydrolysis, Nature Catalysis, 2021, 4, 425-430 (Highlighted by ChemistryViews, 科技日报, 中国科学报)
7. Chen, C. C.;^# Yu, X.; ^# Kuo, C.J.; Min, J.; Chen, S.; Ma, L.;* Liu, K.;*Guo, R. T.* Overview of antiviral drug candidates targeting coronaviral 3C-like main proteases. FEBS Journal, 2021, in press. (Review, https://doi.org/10.1111/febs.15696)
8. Wang, F.; ^#Zhao, J.; ^# Li, Q.; ^# Yang, J.; Li, R.; Min, J.; Yu, X.; Zheng, G.W.; Yu, H.L.; Zhai, C.; Acevedo-Rocha, C.G.; Ma, L.; Li, A* One-pot biocatalytic route from cycloalkanes to α, ω‐dicarboxylic acids by designed Escherichia coli consortia. Nature Communications, 2020, 11, 5035.
9. Zhang, L., Xie, Z., Liu, Z., Zhou, S., Ma, L., Liu, W., Huang, J. W., Ko, T. P., Li, X., Hu, Y., Min, J., Yu, X., Guo, R. T.,* Chen, C. C.* Structural insight into the electron transfer pathway of a self-sufficient P450 monooxygenase. Nature Communications, 2020, 11, 2676. (Highlighted by C&EN, ChemistryViews, 科技日报, 中国科学报)
10. Huang, J.W.; Niu, D.; Liu, K.; Wang, Q.; Ma, L.; Chen, C.C.; Zhang, L.; Liu, W,; Zhou, S.; Min, J.; Wu, Shan.; Yang, Y.; Guo, R.T., Structure basis of non-structural protein pA151R from African Swine Fever Virus, Biochemical and Biophysical Research Communications, in press https://doi.org/10.1016/j.bbrc.2020.08.011
11. Sharma, A.; Toy, W.; Guillen; V. S., Sharma, N.; Min, J.; Carlson, K. E.; Mayne, C. G.; Lin, S.; Sabio, M.; Greene, G., Katzenellenbogen, B. S., Chandarlapaty, S., Katzenellenbogen, J. A., * Antagonists for Constitutively Active Mutant Estrogen Receptors: Insights into the Roles of Antiestrogen-Core and Side-Chain. ACS Chemical Biology, 2018, 13 (12), 3374-3384.
12. Wang, L.; Guillen, V. S.; Sharma, N.; Flessa, K.; Min, J.; Carlson, K. E.; Toy, W.; Braqi, S.; Katzenellenbogen, B. S.; Katzenellenbogen, J. A.; Chandarlapaty, S.; Sharma, A., * New Class of Selective Estrogen Receptor Degraders (SERDs): Expanding the Toolbox of PROTAC Degrons. ACS Medicinal Chemistry Letters, 2018, 9 (8), 803-808.
13. Zhao, Y.; Laws, M. J.; Guillen, V. S.; Ziegler, Y.; Min, J.; Sharma, A.; Kim, S. H.; Chu, D.; Park, B. H.; Oesterreich, S.; Mao, C.; Shapiro, D. J.; Nettles, K. W.; Katzenellenbogen, J. A.; Katzenellenbogen, B. S., * Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors. Cancer Research, 2017, 77 (20), 5602-5613.
14. Srinivasan, S.; Nwachukwu, J. C.; Bruno, N. E.; Dharmarajan, V.; Goswami, D.; Kastrati, I.; Novick, S.; Nowak, J.; Cavett, V.; Zhou, H. B.; Boonmuen, N.; Zhao, Y.; Min, J.; Frasor, J.; Katzenellenbogen, B. S.; Griffin, P. R.; Katzenellenbogen, J. A.; Nettles, K. W., * Full antagonism of the estrogen receptor without a prototypical ligand side chain. Nature Chemical Biology, 2017, 13 (1), 111-118. （入选2017年Faculty of 1000文章）
15. Nwachukwu, J. C.; Srinivasan, S.; Zheng, Y.; Wang, S.; Min, J.; Dong, C.; Liao, Z.; Nowak, J.; Wright, N. J.; Houtman, R.; Carlson, K. E.; Josan, J. S.; Elemento, O.; Katzenellenbogen, J. A.; * Zhou, H. B.; * Nettles, K. W., * Predictive features of ligand-specific signaling through the estrogen receptor. Molecular System Biology, 2016, 12 (4), 864.
16. Zheng, Y.; Zhu, M.; Srinivasan, S.; Nwachukwu, J. C.; Cavett, V.; Min, J.; Carlson, K. E.; Wang, P.; Dong, C.; Katzenellenbogen, J. A.; Nettles, K. W.; Zhou, H.-B., * Development of Selective Estrogen Receptor Modulator (SERM)-Like Activity Through an Indirect Mechanism of Estrogen Receptor Antagonism: Defining the Binding Mode of 7-Oxabicyclo[2.2.1]hept-5-ene Scaffold Core Ligands. ChemMedChem, 2012, 7 (6), 1094-1100.
17. Katzenellenbogen, J.A.*; Katzenellenbogen, B.S.; Min, J.; Kim, S.H.; Antiestrogens For Cancer Therapy, 2018-3-23, 美国, 国际专利号PCT/US18/24144